- RecruitingPHASE2
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
This study looks at new treatments for advanced stomach or gullet cancer. It combines a new drug, ABBV-400, with existing chemotherapy and another new drug, Budigalimab. We want to find the safest and most effective dose and see how well it works.
For: Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Esophageal AdenocarcinomaUnited States · Belgium · Canada - RecruitingPHASE1, PHASE2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
This study looks at new drug combinations for advanced lung cancer. It combines telisotuzumab adizutecan with immune-boosting drugs like budigalimab or pembrolizumab. The goal is to find safe and effective doses to help people with non-small cell lung cancer who haven't had prior treatment for advanced disease.
For: Non Small Cell Lung CarcinomaUnited States · Belgium · China - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living with HIV on Stable Antiretroviral Therapy Undergoing Analytical Treatment Interruption.
This study looks at new medicines (Budigalimab and ABBV-382) for people with HIV. It tests if these medicines can help control HIV without daily treatment, by carefully pausing regular medication. The goal is to see if HIV stays low after stopping usual drugs.
For: HIV infectionGermany · Denmark · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients not Previously Treated for Metastatic Pancreatic Adenocarcinoma
This study is looking at new treatments for advanced pancreatic cancer that has spread. It compares standard chemotherapy with new drug combinations, including Budigalimab and TTX-030, to see which works best and is safest for patients who haven't had treatment for their widespread cancer before.
For: Pancreatic adenocarcinoma metastaticSpain · France · Italy